What is NDC 70166-488?

70166-488 is the product NDC for Atovaquone, Atovaquone 750 mg/5mL suspension, listed with the FDA by Lohxa.

Lohxa, NDC labeler code 70166. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Atovaquone?

19 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Atovaquone NDC 70166-488 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)70166-488Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70166-0488Add the package segment from the table below.

Product information

Brand name (proprietary): Atovaquone
Generic name (nonproprietary): atovaquone
Active ingredients: Atovaquone — 750 mg/5mL
Dosage form: Suspension
Route: Oral
Labeler: LohxaNDC labeler code 70166
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 210692
Marketing start: Oct 11, 2018
Listing expires: Dec 31, 2026
Identifiers: Product ID 70166-488_30ca1c6b-6bc5-3dba-e063-6394a90a5656SPL ID 30ca1c6b-6bc5-3dba-e063-6394a90a5656SPL set ID ba3cad0d-cce9-424f-ba5c-557dba8bef12RxCUI 308429UNII Y883P1Z2LTUPC 0370166488050
Pharmacologic class: Antimalarial; Antiprotozoal

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match: No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

Product label

Current FDA label (SPL), effective Mar 20, 2025.

Indications (excerpt from the label)

Atovaquone oral suspension is a quinone antimicrobial drug indicated for: • Prevention of Pneumocystis jirovecii pneumonia (PCP) in adults and adolescents aged 13 years and older who cannot tolerate trimethoprim-sulfamethoxazole (TMP-SMX).( 1.1) •Treatment of mild-to-moderate PCP in adults and adolescents aged 13 years and older who cannot tolerate TMP-SMX .(1.2) Limitations of Use (1.3): • Treatment of severe PCP (alveolar arterial oxygen diffusion gradient [(A-a)DO 2 ] >45 mm Hg) with atovaquone oral suspension has not been studied. • The efficacy of atovaquone oral suspension in subjects who are failing therapy with TMP-SMX has also not been studied. 1.1 Prevention of Pneumocystis jirovec…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 70166-488

What is NDC 70166-488?: 70166-488 is the product NDC for Atovaquone, Atovaquone 750 mg/5mL suspension, listed with the FDA by Lohxa.
What drug is associated with this NDC?: Atovaquone.
What is the active ingredient?: Atovaquone.
Who is the labeler?: Lohxa, NDC labeler code 70166. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Atovaquone?: 19 other product NDCs are listed under this name. See all Atovaquone NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Atovaquone NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Atovaquone	Atovaquone 750 mg/5mL	SuspensionOral	AvKARE	73190-098	73190-0098-21
Atovaquone	Atovaquone 750 mg/5mL	SuspensionOral	AvPAK	50268-119	50268-0119-12
Atovaquone	Atovaquone 750 mg/5mL	SuspensionOral	PAI Holdings, LLC dba PAI Pharma	0121-0956	00121-0956-08
Atovaquoneatovaquone oral suspension	Atovaquone 750 mg/5mL	SuspensionOral	Major Pharmaceuticals	0904-7459	00904-7459-2500904-7459-53
Atovaquone	Atovaquone 750 mg/5mL	SuspensionOral	Kesin Pharma	81033-104	81033-0104-2281033-0104-4281033-0104-50
Atovaquone	Atovaquone 750 mg/5mL	SuspensionOral	NorthStar RxLLC	72603-248	72603-0248-01
Atovaquone	Atovaquone 750 mg/5mL	SuspensionOral	PAI Holdings, LLC dba PAI Pharma	0121-1016	00121-1016-1800121-1016-42
Atovaquone	Atovaquone 750 mg/5mL	SuspensionOral	Abon Pharmaceuticals, LLC	42239-001	42239-0001-0842239-0001-66
Atovaquone	Atovaquone 750 mg/5mL	SuspensionOral	Bionpharma Inc.	69452-252	69452-0252-87
Atovaquone	Atovaquone 750 mg/5mL	SuspensionOral	Lupin Pharmaceuticals, Inc.	70748-299	70748-0299-01

All 20 Atovaquone NDCs

Other NDCs under ANDA 210692

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 210692
Product	Strength	Form · route	Labeler	Product NDC
Atovaquone	Atovaquone 750 mg/5mL	SuspensionOral	ATLANTIC BIOLOGICALS CORP.	17856-0631
Atovaquone	Atovaquone 750 mg/5mL	SuspensionOral	ATLANTIC BIOLOGICALS CORP.	17856-8631
Atovaquone	Atovaquone 750 mg/5mL	SuspensionOral	Camber Pharmaceuticals, Inc.	31722-629
Atovaquone	Atovaquone 750 mg/5mL	SuspensionOral	American Health Packaging	60687-534
Atovaquone	Atovaquone 750 mg/5mL	SuspensionOral	Lupin Pharmaceuticals, Inc.	70748-299
Atovaquone	Atovaquone 750 mg/5mL	SuspensionOral	NorthStar RxLLC	72603-248